标题/作者	年份
Integrated resistance analysis of CERTAIN-1 and CERTAIN-2 studies in hepatitis C virus-infected patients receiving glecaprevir and pibrentasvir in Japan P Krishnan, G Schnell, R Tripathi, J Beyer, T Reisch, T Dekhtyar, M Irvin, ... Antimicrobial agents and chemotherapy 62 (2), 10.1128/aac. 02217-17	2018
Retreatment of hepatitis C virus-infected patients with direct-acting antiviral failures JM Pawlotsky Seminars in Liver Disease 39 (03), 354-368	2019
Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil VL Ferreira, HHL Borba, A Wiens, MLA Pedroso, VFC Radunz, ... Brazilian Journal of Infectious Diseases 22, 186-192	2018
Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimens KR Reddy, S Pol, PJ Thuluvath, H Kumada, J Toyota, K Chayama, J Levin, ... Liver International 38 (5), 821-833	2018
Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection F Lahser, A Galloway, P Hwang, J Palcza, J Brunhofer, J Wahl, ... Antiviral therapy 23 (7), 593-603	2018
Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus (HCV) NS5A-inhibitor experienced patients with difficult to cure characteristics T Papaluca, SK Roberts, SI Strasser, KA Stuart, G Farrell, G MacQuillan, ... Clinical Infectious Diseases 73 (9), e3288-e3295	2021
An update on direct antiviral agents for the treatment of hepatitis C C Stanciu, CM Muzica, I Girleanu, C Cojocariu, C Sfarti, AM Singeap, ... Expert opinion on pharmacotherapy 22 (13), 1729-1741	2021
Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta‐analysis AM Ahmed, MF Doheim, OM Mattar, NA Sherif, DH Truong, PTL Hoa, ... Journal of medical virology 90 (5), 907-918	2018
Developments in the treatment of HCV genotype 3 infection F McPhee Expert Review of Anti-infective Therapy 17 (10), 775-785	2019
Impact of preexisting hepatitis C virus genotype 6 NS3, NS5A, and NS5B polymorphisms on the in vitro potency of direct-acting antiviral agents F McPhee, J Ueland, V Vellucci, S Bowden, W Sievert, N Zhou Antimicrobial Agents and Chemotherapy 63 (4), 10.1128/aac. 02205-18	2019
Efficacy and safety of a fixed dose combination tablet of asunaprevir+ beclabuvir+ daclatasvir for the treatment of Hepatitis C E Zappulo, R Scotto, AR Buonomo, AE Maraolo, B Pinchera, I Gentile Expert Opinion on Pharmacotherapy 21 (3), 261-273	2020
Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C J Itakura, M Kurosaki, S Kakizaki, K Amano, N Nakayama, J Inoue, T Endo, ... JHEP Reports 2 (5), 100138	2020
Frequency of baseline NS5A resistance-associated substitutions in patients infected with genotype 1 of hepatitis C virus in Croatia P Simicic, I Grgic, M Santak, A Vince, SZ Lepej Microbial pathogenesis 136, 103694	2019
Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse D Bonsall, S Black, AYM Howe, R Chase, P Ingravallo, I Pak, A Brown, ... Infection and Drug Resistance, 1119-1135	2018
Durability of sustained virologic response and improvement of fibrosis markers after daclatasvir and asunaprevir treatment in genotype 1b hepatitis C virus-infected patients: a real life and multicenter study SK Shin, JW Lee, H Ra, OS Kwon, JB Shin, YJ Jin, S Lee, KJ Han, YN Kim, ... Journal of Korean Medical Science 34 (41)	2019
Performance assessment of a fully automated deep sequencing platform for HCV resistance testing C Rodriguez, M Mercier-Darty, A Soulier, L Poiteau, M Wlassow, S Fourati, ... Antiviral Therapy 24 (6), 417-423	2019
Exposure‐Response Analysis for Efficacy of Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV‐Infected Patients T Ueno, M Osawa, T Shiozaki, M Green, T Garimella Clinical pharmacology in drug development 8 (7), 903-913	2019
Minor contribution of CYP3A5 to the metabolism of hepatitis C protease inhibitor paritaprevir in vitro SN San, J Matsumoto, Y Saito, M Koike, H Sakaue, Y Kato, M Fujiyoshi, ... Xenobiotica 49 (8), 935-944	2019
In vitro antiviral profile of ruzasvir, a potent and pangenotype inhibitor of hepatitis C virus NS5a E Asante-Appiah, R Liu, S Curry, P McMonagle, S Agrawal, D Carr, ... Antimicrobial Agents and Chemotherapy 62 (11), 10.1128/aac. 01280-18	2018
Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C I Esposito, S Marciano, J Trinks Expert Opinion on Drug Metabolism & Toxicology 14 (6), 649-657	2018

1 - 20

计算机程序会自动估算并确定日期和引用次数。